Swiss Startup Life Biosystems Signs 10-Year ‘In Silico Discovery’ Deal with MD Anderson
April 25, 2008
Swiss Startup Life Biosystems Signs 10-Year ‘In Silico Discovery’ Deal with MD Anderson
Life Biosystems officials said the agreement is key to the company’s business strategy because it provides clinical data that will drive its discovery efforts, as well as access to research partners at the institute that can help validate the company’s discoveries.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Philips Research Plans Clinical Study for Software to Help Oncologists Interpret NGS Data
May 17, 2013 / BioInform - InSilico Genomics to Use $1.5M in Seed Money to Improve Bioinformatics Infrastructure
May 17, 2013 / BioInform - Q&A: BU Scientists Discuss Informatics Education Needs for Translational Researchers
May 17, 2013 / BioInform - System Biosciences Taps Maverix's Platform for Exosome Sequence Analytics Service
May 17, 2013 / BioInform - Belgium's VIB Licenses Biogazelle's Qbase+ for PCR Data Analysis
May 17, 2013 / BioInform